Unum Group

UNM · NYSE

$93.43+$1.66 (+1.81%)TodayMarket closed · Oct 20, 7:32 PM ET

Prev close $91.77

UNM analyst rating

BuyConsensus of 13 analysts over the last 12 months. 62% rate it a buy.

Strong buy0
Buy8
Hold5
Underperform0
Sell0

12-month price target · 15 analysts

Average $99.88 (+6.9% upside)

Low: $49.43
Now: $93.43
High: $128.10

Upgrades and downgrades

The latest rating actions, newest first

UNM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 12, 2026	Maintains	Overweight	$100.00 → $102.00	75%
Barclays	Oct 7, 2026	Maintains	Overweight	$110.00 → $109.00	61%
Morgan Stanley	Aug 24, 2026	Maintains	Equal-Weight	$87.00 → $92.00	59%
JP Morgan	Aug 3, 2026	Maintains	Neutral	$101.00 → $98.00	81%
Keefe, Bruyette & Woods	Jul 30, 2026	Maintains	Outperform	$110.00 → $108.00	71%
JP Morgan	Jul 21, 2026	Maintains	Neutral	$90.00 → $101.00	81%
Evercore ISI Group	Jul 13, 2026	Maintains	Outperform	$106.00 → $111.00	59%
Jefferies	Jul 10, 2026	Maintains	Buy	$117.00 → $123.00	76%
Wells Fargo	Jul 9, 2026	Maintains	Overweight	$100.00 → $101.00	75%
Evercore ISI Group	Jul 7, 2026	Maintains	Outperform	$103.00 → $106.00	59%

The case for and against

Updated Jan 19, 2026

Bull case

Unum Group operates in a steadily improving life insurance industry, characterized by enhanced returns, reduced liability risks, and strong free cash flow conversion. The company benefits from a favorable operating environment driven by higher interest rates, demographic trends, and technological advancements, contributing to mid-single-digit premium growth and robust profitability. Additionally, Unum maintains a competitive advantage through its established group benefits franchise, which generates over 20% return on equity (ROE) and exhibits more than 90% free cash flow conversion.

Bear case

Unum Group's earnings per share (EPS) estimates for 2025 and 2026 have been downgraded to $8.48 and $9.25, respectively, due to higher group disability benefit ratios projected at 62% and 63%, signaling increased costs related to claims. Additionally, a slight decrease in closed block earnings has raised concerns about the sustainability of revenue from this segment, further contributing to the cautious outlook. Increased long-term care incidence rates and potential GAAP assumption review risks add to the uncertainty surrounding the company's financial health, despite indicating no immediate capital risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.